ES8604424A1 - Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983 - Google Patents

Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983

Info

Publication number
ES8604424A1
ES8604424A1 ES538727A ES538727A ES8604424A1 ES 8604424 A1 ES8604424 A1 ES 8604424A1 ES 538727 A ES538727 A ES 538727A ES 538727 A ES538727 A ES 538727A ES 8604424 A1 ES8604424 A1 ES 8604424A1
Authority
ES
Spain
Prior art keywords
antibodies
preparation
uses therefor
polydomas
target antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES538727A
Other languages
English (en)
Other versions
ES538727A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES538727A0 publication Critical patent/ES538727A0/es
Publication of ES8604424A1 publication Critical patent/ES8604424A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROCEDIMIENTO PARA OBTENER UN HIBRIDOMA SELECTIVAMENTE DESTRUCTIBLE. CONSISTENTE EN: HACER REACCIONAR EL HIBRIDOMA CON UN COMPUESTO ANALOGO DE UN SUSTRATO DE ENZIMA, TAL COMO LA AZASERINA O 5-DIANO-5-OXA-L-NORLEUCINA, EN EL SITIO DE ACTIVIDAD DEL ENZIMA, PARA LOGRAR LA INHIBICION IRREVERSIBLE DEL ENZIMA Y FINALMENTE LA MUERTE DEL HIBRIDOMA. EL HIBRIDOMA SELECTIVAMENTE DESTRUCTIBLE OBTENIDO PRODUCE UN ANCITUCERPO MONOCLONAL CONTRA UN PRIMER DETERMINANTE ANTIGENICO Y PUEDE FUSIONARSE CON UN LINFOCITO B TAL COMO UNA CELULA DE BAZO DE UN MAMIFERO, QUE SEGREGA UN ANTICUERPO MONOCLONAL CONTRA UN SEGUNDO DETERMINANTE ANTIGENICO EN PRESENCIA DE UN AGENTE PROMOTOR DE LA FUSION TAL COMO POLIETILENGLICOL O VIRUS SENDI. SE UTILIZA EN PROCEDIMIENTOS DE INMUNODIAGNOSTICO E INMUNOTERAPIA, Y TECNOLOGIA RELACIONADA CON ANTICUERPOS, MONOCLONALES O CON ESPECIFICIDAD DUAL.
ES538727A 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983 Expired ES8604424A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES538727A0 ES538727A0 (es) 1986-02-01
ES8604424A1 true ES8604424A1 (es) 1986-02-01

Family

ID=23448582

Family Applications (7)

Application Number Title Priority Date Filing Date
ES521370A Expired ES8504461A1 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Granted ES527963A0 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533930A Expired ES8603080A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533931A Granted ES533931A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Family Applications Before (5)

Application Number Title Priority Date Filing Date
ES521370A Expired ES8504461A1 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Granted ES527963A0 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533930A Expired ES8603080A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533931A Granted ES533931A0 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Country Status (11)

Country Link
EP (1) EP0105360A4 (es)
JP (2) JPH0753119B2 (es)
AT (1) AT394577B (es)
AU (1) AU550486B2 (es)
CA (1) CA1213229A (es)
CH (1) CH672796A5 (es)
ES (7) ES8504461A1 (es)
FI (1) FI834529A0 (es)
GB (4) GB2128631B (es)
IT (1) IT1219778B (es)
WO (1) WO1983003679A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
CA1214123A (en) * 1983-01-20 1986-11-18 Masashi Matsui Cell lines for use in the preparation of hybridoma cells
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3583278D1 (de) * 1984-04-23 1991-07-25 Boston Biomed Res Inst Doppelspezifische antikoerper-determinanten.
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
WO1987006240A1 (en) 1986-04-14 1987-10-22 The General Hospital Corporation Heterobifunctional antibodies and method of use
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
EP0308936B1 (en) * 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
WO1991012023A2 (en) * 1990-02-16 1991-08-22 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
IE921342A1 (en) * 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
WO1998012334A2 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
HUE027549T2 (hu) 2002-07-31 2016-10-28 Seattle Genetics Inc Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére
KR101192496B1 (ko) 2003-11-06 2012-10-18 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
EA012980B1 (ru) 2004-03-16 2010-02-26 Темпл Юниверсити Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Замещённые фенокси- и фенилтиопроизводные для лечения пролиферативных нарушений
CA2586909A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
CN101646431B (zh) 2007-01-22 2012-06-27 健泰科生物技术公司 蛋白质的聚电解质沉淀和纯化
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
DK2968440T3 (da) 2013-03-15 2019-07-22 Zymeworks Inc Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
US10227407B2 (en) 2013-10-10 2019-03-12 Yukinari Kato Anti-podoplanin antibody
MX2016008444A (es) 2013-12-27 2017-01-11 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de farmacos.
PL3194421T3 (pl) 2014-09-17 2022-02-28 Zymeworks Inc. Związki cytotoksyczne i przeciwmitotyczne oraz sposoby ich wykorzystania
EP3165532B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Auristatin derivatives, linker-drugs and ligand-drug conjugates
EA201892040A1 (ru) 2016-03-25 2019-04-30 Сиэтл Дженетикс, Инк. Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
AU2019327490A1 (en) * 2018-08-30 2021-03-25 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
CA3139809A1 (en) 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
IL309405A (en) 2021-06-29 2024-02-01 Seagen Inc Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
AU1555983A (en) 1983-11-04
GB8530309D0 (en) 1986-01-22
JPH0753600A (ja) 1995-02-28
ES537257A0 (es) 1986-04-01
ES521370A0 (es) 1985-04-16
FI834529A (fi) 1983-12-09
GB2168998A (en) 1986-07-02
ES533930A0 (es) 1985-12-01
WO1983003679A1 (en) 1983-10-27
GB8530310D0 (en) 1986-01-22
IT1219778B (it) 1990-05-24
ES8504461A1 (es) 1985-04-16
ES538727A0 (es) 1986-02-01
AU550486B2 (en) 1986-03-20
ES8503441A1 (es) 1985-02-16
GB2128631A (en) 1984-05-02
ES8506091A1 (es) 1985-06-16
GB2167086A (en) 1986-05-21
CA1213229A (en) 1986-10-28
IT8320548A0 (it) 1983-04-12
ES8603080A1 (es) 1985-12-01
FI834529A0 (fi) 1983-12-09
EP0105360A1 (en) 1984-04-18
ES8606655A1 (es) 1986-04-01
ES527963A0 (es) 1985-02-16
JP2562002B2 (ja) 1996-12-11
EP0105360A4 (en) 1986-07-08
GB2167086B (en) 1987-03-04
GB2168998B (en) 1987-03-04
GB8530308D0 (en) 1986-01-22
ES545247A0 (es) 1986-05-16
GB2169921A (en) 1986-07-23
AT394577B (de) 1992-05-11
CH672796A5 (es) 1989-12-29
JPS6312276A (ja) 1988-01-19
GB2169921B (en) 1987-03-04
GB8332646D0 (en) 1984-01-11
JPH0753119B2 (ja) 1995-06-07
ATA901883A (de) 1991-10-15
GB2128631B (en) 1987-02-25
ES8607386A1 (es) 1986-05-16
ES533931A0 (es) 1985-06-16

Similar Documents

Publication Publication Date Title
ES8604424A1 (es) Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
JPS6447378A (en) Monoclonal antibody to black tumor related antigen, hybrid cell line for producing the same and use thereof
JPS6413988A (en) Hybridoma
DK450183D0 (da) Humane monoklone antistoffer mod et bakterietoksin samt disses fremstilling, kontinuerlige cellelinier, som producerer antitoksinantistoffer, samt antistoffernes anvendelser
IL80231A (en) Monoclonal anti-human breast cancer antibodies and hybridomas producing them,and diagnosis of human breast tumors
ZA833686B (en) Human human hybridomas for cervical carcinoma
PH16642A (en) Complement-fixing monoclonal antibody to human t cells,and methods of preparing same
IE800565L (en) Monoclonal antibodies to human t cells
EP0419574A4 (en) Monoclonal antibodies to the light chain region of human factor xii and methods of preparing and using the same
DE3070744D1 (en) Hybrid cell line for producing complement-fixing, monoclonal antibody to human suppressor t cells, antibody, method of preparation of this antibody, diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody
DE3485432D1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
AU545181B2 (en) Hybridoma for producing monoclonal antibodies
AU545222B2 (en) Hybridoma for producing monoconal antibodies
GB8609058D0 (en) Monoclonal antibodies
EP0351045A3 (en) Monoclonal antibody nuh2 capable of inactivating motility of sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen
ES2000615A6 (es) Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"
GR3020387T3 (en) Ctaa 28a32, the antigen recognized by mca 28a32
ES8401982A1 (es) "procedimiento de preparacion de globulina antilinfocitaria t".
EP0089771A3 (en) Atcc hb8116 and its monoclonal anti-h-y antibody, hyclonalan

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970401